# Encoded Therapeutics

> Clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders.

## Why it is interesting

Its $275M Series F funds ETX101 pivotal development in Dravet syndrome, internal GMP scale-up, and a broader neurology pipeline.

## Profile

- **Latest funding:** Series F — $275M (September 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $275M
- **Stage:** growth
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-09-12
- **Latest funding investors:** GV, Undisclosed healthcare fund, ARCH Venture Partners, RTW Investments

## Key facts

- $275M Series F closed Sep 9, 2026, co-led by GV and an unnamed healthcare fund
- ETX101 pivotal and expansion studies in Dravet syndrome
- ETX301 targeted for a 2027 IND submission

## Funding history

- Series F · $275M · September 2026
  Source: Https://encoded.com/encoded-therapeutics-raises-275-million-in-series-f-financing-to-advance-etx101-through-pivotal-development-and-accelerate-its-precision-genetic-medicines-neurology-pipeline/

## Related articles

- https://venturecapitaltracker.com/2026-encoded-therapeutics-275m-series-f-dravet
- https://venturecapitaltracker.com/2026-september-11-12-investment-news-chips-biotech-fintech

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** September 12, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/encoded-therapeutics